Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T- Cell Therapy in the US

被引：0

作者：

Epperla, Narendranath ^{[1
]}

Lucero, Melanie ^{[2
]}

Bailey, Tom ^{[3
]}

Mirams, Laura ^{[3
]}

Cheung, Jolenta ^{[3
]}

Amet, Mona ^{[3
]}

Milligan, Gary ^{[3
]}

Keir, Chris ^{[4
]}

Chen, Lei ^{[5
]}

机构：

[1] Ohio State Univ, Columbus, OH USA

[2] ADC Therapeut Amer Inc, New Providence, NJ USA

[3] Adelphi Real World, Macclesfield, Cheshire, England

[4] ADC Therapeut, Murray Hill, NJ USA

[5] ADC Therapeut, New Providence, NJ USA

来源：

关键词：

loncastuximab tesirine; CD19-targeted chimeric antigen receptor T-cell therapy; real-world evidence; treatment sequencing;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-370

引用

页码：S476 / S476

页数：1